Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Clinical trial NCT06151847 · COMPLETED

Trial details

NCT number: NCT06151847
Sponsor: University of Kansas Medical Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Melanoma Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Unresectable Melanoma

Start date: 2023-12-21
Primary completion: 2025-07-10
Enrollment: 11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.